Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.
Market Analysis and Insights: Global Acute Myeloid Leukemia Market
The global Acute Myeloid Leukemia market size is projected to reach US$ 1344.9 million by 2026, from US$ 1179.5 million in 2020, at a CAGR of 13.0%% during 2021-2026.
Global Acute Myeloid Leukemia Scope and Market Size
Acute Myeloid Leukemia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acute Myeloid Leukemia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Acute Myeloid Leukemia Breakdown Data by Type
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Acute Myeloid Leukemia Breakdown Data by Application
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.
Market Analysis and Insights: Global Acute Myeloid Leukemia Market
The global Acute Myeloid Leukemia market size is projected to reach US$ 1344.9 million by 2026, from US$ 1179.5 million in 2020, at a CAGR of 13.0%% during 2021-2026.
Global Acute Myeloid Leukemia Scope and Market Size
Acute Myeloid Leukemia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acute Myeloid Leukemia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Acute Myeloid Leukemia Breakdown Data by Type
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Acute Myeloid Leukemia Breakdown Data by Application
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Acute Myeloid Leukemia Revenue
1.4 Market by Type
1.4.1 Global Acute Myeloid Leukemia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Stem Cell Transplant
1.4.5 Targeted Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Acute Myeloid Leukemia Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Retails Drug Stores
1.5.4 Ambulatory Care Centers
1.5.5 Oncology Centers
1.5.6 Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia Market Perspective (2015-2026)
2.2 Global Acute Myeloid Leukemia Growth Trends by Regions
2.2.1 Acute Myeloid Leukemia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Acute Myeloid Leukemia Historic Market Share by Regions (2015-2020)
2.2.3 Acute Myeloid Leukemia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Acute Myeloid Leukemia Market Growth Strategy
2.3.6 Primary Interviews with Key Acute Myeloid Leukemia Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia Players by Market Size
3.1.1 Global Top Acute Myeloid Leukemia Players by Revenue (2015-2020)
3.1.2 Global Acute Myeloid Leukemia Revenue Market Share by Players (2015-2020)
3.1.3 Global Acute Myeloid Leukemia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Acute Myeloid Leukemia Market Concentration Ratio
3.2.1 Global Acute Myeloid Leukemia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Revenue in 2019
3.3 Acute Myeloid Leukemia Key Players Head office and Area Served
3.4 Key Players Acute Myeloid Leukemia Product Solution and Service
3.5 Date of Enter into Acute Myeloid Leukemia Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acute Myeloid Leukemia Historic Market Size by Type (2015-2020)
4.2 Global Acute Myeloid Leukemia Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Acute Myeloid Leukemia Market Size by Application (2015-2020)
5.2 Global Acute Myeloid Leukemia Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Acute Myeloid Leukemia Market Size (2015-2020)
6.2 Acute Myeloid Leukemia Key Players in North America (2019-2020)
6.3 North America Acute Myeloid Leukemia Market Size by Type (2015-2020)
6.4 North America Acute Myeloid Leukemia Market Size by Application (2015-2020)
7 Europe
7.1 Europe Acute Myeloid Leukemia Market Size (2015-2020)
7.2 Acute Myeloid Leukemia Key Players in Europe (2019-2020)
7.3 Europe Acute Myeloid Leukemia Market Size by Type (2015-2020)
7.4 Europe Acute Myeloid Leukemia Market Size by Application (2015-2020)
8 China
8.1 China Acute Myeloid Leukemia Market Size (2015-2020)
8.2 Acute Myeloid Leukemia Key Players in China (2019-2020)
8.3 China Acute Myeloid Leukemia Market Size by Type (2015-2020)
8.4 China Acute Myeloid Leukemia Market Size by Application (2015-2020)
9 Japan
9.1 Japan Acute Myeloid Leukemia Market Size (2015-2020)
9.2 Acute Myeloid Leukemia Key Players in Japan (2019-2020)
9.3 Japan Acute Myeloid Leukemia Market Size by Type (2015-2020)
9.4 Japan Acute Myeloid Leukemia Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Acute Myeloid Leukemia Market Size (2015-2020)
10.2 Acute Myeloid Leukemia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Acute Myeloid Leukemia Market Size by Type (2015-2020)
10.4 Southeast Asia Acute Myeloid Leukemia Market Size by Application (2015-2020)
11 India
11.1 India Acute Myeloid Leukemia Market Size (2015-2020)
11.2 Acute Myeloid Leukemia Key Players in India (2019-2020)
11.3 India Acute Myeloid Leukemia Market Size by Type (2015-2020)
11.4 India Acute Myeloid Leukemia Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Acute Myeloid Leukemia Market Size (2015-2020)
12.2 Acute Myeloid Leukemia Key Players in Central & South America (2019-2020)
12.3 Central & South America Acute Myeloid Leukemia Market Size by Type (2015-2020)
12.4 Central & South America Acute Myeloid Leukemia Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Celgene Corporation
13.1.1 Celgene Corporation Company Details
13.1.2 Celgene Corporation Business Overview
13.1.3 Celgene Corporation Acute Myeloid Leukemia Introduction
13.1.4 Celgene Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020))
13.1.5 Celgene Corporation Recent Development
13.2 Cephalon
13.2.1 Cephalon Company Details
13.2.2 Cephalon Business Overview
13.2.3 Cephalon Acute Myeloid Leukemia Introduction
13.2.4 Cephalon Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.2.5 Cephalon Recent Development
13.3 Clavis Pharma
13.3.1 Clavis Pharma Company Details
13.3.2 Clavis Pharma Business Overview
13.3.3 Clavis Pharma Acute Myeloid Leukemia Introduction
13.3.4 Clavis Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.3.5 Clavis Pharma Recent Development
13.4 Eisai
13.4.1 Eisai Company Details
13.4.2 Eisai Business Overview
13.4.3 Eisai Acute Myeloid Leukemia Introduction
13.4.4 Eisai Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.4.5 Eisai Recent Development
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Details
13.5.2 Genzyme Corporation Business Overview
13.5.3 Genzyme Corporation Acute Myeloid Leukemia Introduction
13.5.4 Genzyme Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.5.5 Genzyme Corporation Recent Development
13.6 Sunesis Pharmaceuticals
13.6.1 Sunesis Pharmaceuticals Company Details
13.6.2 Sunesis Pharmaceuticals Business Overview
13.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Introduction
13.6.4 Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.6.5 Sunesis Pharmaceuticals Recent Development
13.7 Abbvie
13.7.1 Abbvie Company Details
13.7.2 Abbvie Business Overview
13.7.3 Abbvie Acute Myeloid Leukemia Introduction
13.7.4 Abbvie Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.7.5 Abbvie Recent Development
13.8 Astellas Pharma
13.8.1 Astellas Pharma Company Details
13.8.2 Astellas Pharma Business Overview
13.8.3 Astellas Pharma Acute Myeloid Leukemia Introduction
13.8.4 Astellas Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.8.5 Astellas Pharma Recent Development
13.9 CTI Biopharma Corp
13.9.1 CTI Biopharma Corp Company Details
13.9.2 CTI Biopharma Corp Business Overview
13.9.3 CTI Biopharma Corp Acute Myeloid Leukemia Introduction
13.9.4 CTI Biopharma Corp Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.9.5 CTI Biopharma Corp Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Acute Myeloid Leukemia Revenue
1.4 Market by Type
1.4.1 Global Acute Myeloid Leukemia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Stem Cell Transplant
1.4.5 Targeted Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Acute Myeloid Leukemia Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Retails Drug Stores
1.5.4 Ambulatory Care Centers
1.5.5 Oncology Centers
1.5.6 Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia Market Perspective (2015-2026)
2.2 Global Acute Myeloid Leukemia Growth Trends by Regions
2.2.1 Acute Myeloid Leukemia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Acute Myeloid Leukemia Historic Market Share by Regions (2015-2020)
2.2.3 Acute Myeloid Leukemia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Acute Myeloid Leukemia Market Growth Strategy
2.3.6 Primary Interviews with Key Acute Myeloid Leukemia Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia Players by Market Size
3.1.1 Global Top Acute Myeloid Leukemia Players by Revenue (2015-2020)
3.1.2 Global Acute Myeloid Leukemia Revenue Market Share by Players (2015-2020)
3.1.3 Global Acute Myeloid Leukemia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Acute Myeloid Leukemia Market Concentration Ratio
3.2.1 Global Acute Myeloid Leukemia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Revenue in 2019
3.3 Acute Myeloid Leukemia Key Players Head office and Area Served
3.4 Key Players Acute Myeloid Leukemia Product Solution and Service
3.5 Date of Enter into Acute Myeloid Leukemia Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acute Myeloid Leukemia Historic Market Size by Type (2015-2020)
4.2 Global Acute Myeloid Leukemia Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Acute Myeloid Leukemia Market Size by Application (2015-2020)
5.2 Global Acute Myeloid Leukemia Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Acute Myeloid Leukemia Market Size (2015-2020)
6.2 Acute Myeloid Leukemia Key Players in North America (2019-2020)
6.3 North America Acute Myeloid Leukemia Market Size by Type (2015-2020)
6.4 North America Acute Myeloid Leukemia Market Size by Application (2015-2020)
7 Europe
7.1 Europe Acute Myeloid Leukemia Market Size (2015-2020)
7.2 Acute Myeloid Leukemia Key Players in Europe (2019-2020)
7.3 Europe Acute Myeloid Leukemia Market Size by Type (2015-2020)
7.4 Europe Acute Myeloid Leukemia Market Size by Application (2015-2020)
8 China
8.1 China Acute Myeloid Leukemia Market Size (2015-2020)
8.2 Acute Myeloid Leukemia Key Players in China (2019-2020)
8.3 China Acute Myeloid Leukemia Market Size by Type (2015-2020)
8.4 China Acute Myeloid Leukemia Market Size by Application (2015-2020)
9 Japan
9.1 Japan Acute Myeloid Leukemia Market Size (2015-2020)
9.2 Acute Myeloid Leukemia Key Players in Japan (2019-2020)
9.3 Japan Acute Myeloid Leukemia Market Size by Type (2015-2020)
9.4 Japan Acute Myeloid Leukemia Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Acute Myeloid Leukemia Market Size (2015-2020)
10.2 Acute Myeloid Leukemia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Acute Myeloid Leukemia Market Size by Type (2015-2020)
10.4 Southeast Asia Acute Myeloid Leukemia Market Size by Application (2015-2020)
11 India
11.1 India Acute Myeloid Leukemia Market Size (2015-2020)
11.2 Acute Myeloid Leukemia Key Players in India (2019-2020)
11.3 India Acute Myeloid Leukemia Market Size by Type (2015-2020)
11.4 India Acute Myeloid Leukemia Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Acute Myeloid Leukemia Market Size (2015-2020)
12.2 Acute Myeloid Leukemia Key Players in Central & South America (2019-2020)
12.3 Central & South America Acute Myeloid Leukemia Market Size by Type (2015-2020)
12.4 Central & South America Acute Myeloid Leukemia Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Celgene Corporation
13.1.1 Celgene Corporation Company Details
13.1.2 Celgene Corporation Business Overview
13.1.3 Celgene Corporation Acute Myeloid Leukemia Introduction
13.1.4 Celgene Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020))
13.1.5 Celgene Corporation Recent Development
13.2 Cephalon
13.2.1 Cephalon Company Details
13.2.2 Cephalon Business Overview
13.2.3 Cephalon Acute Myeloid Leukemia Introduction
13.2.4 Cephalon Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.2.5 Cephalon Recent Development
13.3 Clavis Pharma
13.3.1 Clavis Pharma Company Details
13.3.2 Clavis Pharma Business Overview
13.3.3 Clavis Pharma Acute Myeloid Leukemia Introduction
13.3.4 Clavis Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.3.5 Clavis Pharma Recent Development
13.4 Eisai
13.4.1 Eisai Company Details
13.4.2 Eisai Business Overview
13.4.3 Eisai Acute Myeloid Leukemia Introduction
13.4.4 Eisai Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.4.5 Eisai Recent Development
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Details
13.5.2 Genzyme Corporation Business Overview
13.5.3 Genzyme Corporation Acute Myeloid Leukemia Introduction
13.5.4 Genzyme Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.5.5 Genzyme Corporation Recent Development
13.6 Sunesis Pharmaceuticals
13.6.1 Sunesis Pharmaceuticals Company Details
13.6.2 Sunesis Pharmaceuticals Business Overview
13.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Introduction
13.6.4 Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.6.5 Sunesis Pharmaceuticals Recent Development
13.7 Abbvie
13.7.1 Abbvie Company Details
13.7.2 Abbvie Business Overview
13.7.3 Abbvie Acute Myeloid Leukemia Introduction
13.7.4 Abbvie Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.7.5 Abbvie Recent Development
13.8 Astellas Pharma
13.8.1 Astellas Pharma Company Details
13.8.2 Astellas Pharma Business Overview
13.8.3 Astellas Pharma Acute Myeloid Leukemia Introduction
13.8.4 Astellas Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.8.5 Astellas Pharma Recent Development
13.9 CTI Biopharma Corp
13.9.1 CTI Biopharma Corp Company Details
13.9.2 CTI Biopharma Corp Business Overview
13.9.3 CTI Biopharma Corp Acute Myeloid Leukemia Introduction
13.9.4 CTI Biopharma Corp Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.9.5 CTI Biopharma Corp Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
